Vitoss is expected to launch in the U.S. in 9-12 months, after the introduction of Vitoss BA2X, which will be commercially introduced next week. The product is a non-structural bone void filler for use in the extremities, pelvis and posterolateral spine.
Vitoss BA Biodal differs from the previous versions of Vitoss BA by modifying the size distribution of bioactive glass particles to accelerate the resorption of the bioactive glass.
Read the release about Vitoss BA Biomodal from Orthovita.
Read other coverage on orthopedic and spine devices:
– Wright Medical Group Releases EVOLVE Elbow Plating System
– OrthoPathways Group Plans to Launch Stamina Knee System
– Biomet Receives FDA 510(k) Clearance for Signature Personalized Total Knee Replacement System
